$26.81
+0.24 (+0.90%)
Open$26.84
Previous Close$26.57
Day High$27.17
Day Low$26.19
52W High$31.34
52W Low$15.79
Volume—
Avg Volume700.4K
Market Cap1.86B
P/E Ratio—
EPS$-2.01
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-33.4% upside
Current
$26.81
$26.81
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 99.72M | 156.86M | 182.20M |
| Net Income | -76,345,048 | -108,086,429 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -83,639,658 | -124,992,410 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |